- Home
- SLDB
as 07-26-2024 4:00pm EST
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 382.4M | IPO Year: | 2018 |
| Target Price: | $17.10 | AVG Volume (30 days): | 708.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $15.05 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 63.73% |
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kahn Clare | SLDB | Director | Jun 7 '24 | Buy | $7.67 | 1,100 | $8,441.62 | 1,100 | SEC Form 4 |
| Ganot Ilan | SLDB | Director | May 2 '24 | Sell | $10.33 | 462 | $4,772.46 | 9,507 | SEC Form 4 |
| Ganot Ilan | SLDB | Director | Jan 27 '24 | Sell | $7.99 | 139 | $1,110.61 | 8,416 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | SLDB | Director10% Owner | Jan 11 '24 | Buy | $5.53 | 3,410,713 | $18,861,242.89 | 6,833,539 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | SLDB | Director10% Owner | Jan 11 '24 | Buy | $5.53 | 904,160 | $5,000,004.80 | 4,192,216 | SEC Form 4 |
| Tan Kevin | SLDB | CFO & Treasurer | Jan 9 '24 | Sell | $8.20 | 3,935 | $32,267.00 | 9,308 | SEC Form 4 |
| Ganot Ilan | SLDB | Director | Jan 3 '24 | Sell | $5.30 | 1,142 | $6,052.49 | 8,167 | SEC Form 4 |
| Marlowe Jennifer | SLDB | CSO | Dec 2 '23 | Sell | $2.77 | 4,890 | $13,524.76 | 6,998 | SEC Form 4 |
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Dec 2 '23 | Sell | $2.78 | 4,879 | $13,561.67 | 6,983 | SEC Form 4 |
| Howton David T | SLDB | Chief Operating Officer | Dec 2 '23 | Sell | $2.78 | 5,367 | $14,920.26 | 7,684 | SEC Form 4 |
| Herzich Paul | SLDB | Chief Technology Officer | Dec 2 '23 | Sell | $2.77 | 2,968 | $8,232.34 | 4,270 | SEC Form 4 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Solid Biosciences Shares Rise After JPMorgan Upgrade
MT Newswires
12 days ago
JPMorgan Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $15 From $10
GlobeNewswire
25 days ago
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
25 days ago
Solid Biosciences Joins Russell 3000 Index
GlobeNewswire
a month ago
Solid Biosciences Joins the Russell 3000® Index
MT Newswires
a month ago
Leerink Partners Upgrades Solid Biosciences to Outperform From Market Perform, Price Target is $12
MT Newswires
a month ago
Top Premarket Gainers
PR Newswire
2 months ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Compare SLDB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.